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Pioglitazone Enhances the 
Beneficial Effects of Glucocorticoids 
in Experimental Nephrotic 
Syndrome
S. Agrawal1, M. A. Chanley1, D. Westbrook2, X. Nie1, T. Kitao1, A. J. Guess1, R. Benndorf1,3, 
G. Hidalgo2,4 & W. E. Smoyer1,3
Glucocorticoids are the primary therapy for nephrotic syndrome (NS), but have serious side effects 
and are ineffective in ~20–50% of patients. Thiazolidinediones have recently been suggested to be 
renoprotective, and to modulate podocyte glucocorticoid-mediated nuclear receptor signaling. We 
hypothesized that thiazolidinediones could enhance glucocorticoid efficacy in NS. We found that 
puromycin aminonucleoside-induced proteinuria in rats was significantly reduced by both high-dose 
glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25%). Remarkably, 
pioglitazone + low-dose glucocorticoids also reduced proteinuria (63%) comparably to high-dose 
glucocorticoids, whereas pioglitazone + high-dose glucocorticoids reduced proteinuria to almost 
control levels (97%). Molecular analysis revealed that both glucocorticoids and pioglitazone enhanced 
glomerular synaptopodin and nephrin expression, and reduced COX-2 expression, after injury. 
Furthermore, the glomerular phosphorylation of glucocorticoid receptor and Akt, but not PPARγ, 
correlated with treatment-induced reductions in proteinuria. Notably, clinical translation of these 
findings to a child with refractory NS by the addition of pioglitazone to the treatment correlated with 
marked reductions in both proteinuria (80%) and overall immunosuppression (64%). These findings 
together suggest that repurposing pioglitazone could potentially enhance the proteinuria-reducing 
effects of glucocorticoids during NS treatment.
Nephrotic syndrome (NS) is among the most common kidney diseases affecting both children and adults. 
Oral glucocorticoids (GCs) have been the primary therapy for NS in both children and adults for >60 years, 
although GCs have serious side effects and are clinically ineffective in ~20% of children and ~50% of adults1,2. 
Unfortunately most alternative agents are only partially effective, and are associated with significant side effects3. 
Thus, there is a critical need for both more effective and less toxic treatments for NS.
In this context, the FDA-approved type II diabetes drugs, thiazolidinediones (TZDs), have been shown in 
large observational studies to slow the progression of diabetic nephropathy and to reduce proteinuria, poten-
tially due to their direct renoprotective effects in addition to their known promoting effects on insulin sensi-
tivity4. Although the mechanism of action for such protection remains unclear, recent laboratory studies have 
reported partial protective effects of TZDs in animal models of nephropathy5–8, as well as in direct podocyte 
injury in vitro9–12. Notably, both GCs and TZDs are known to act via a similar molecular mechanism by binding 
to their respective nuclear receptors [glucocorticoid receptor (GR) and peroxisome proliferator-activated recep-
tor gamma (PPARγ ), respectively], both of which belong to the nuclear hormone receptor superfamily13,14. We 
recently reported direct protective effects of GCs and TZDs on podocytes, potentially due to crosstalk between 
the GC and TZD nuclear receptor-mediated signaling pathways, as demonstrated by the ability of TZDs to mod-
ulate the GC signaling pathway10. We thus hypothesized that nuclear receptor crosstalk between podocyte TZD 
and GC pathways could be exploited to enhance the proteinuria-reducing effects of GCs during NS treatment. 
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To test this hypothesis we: 1) Determined the ability of pioglitazone to protect and enhance the efficacy of GCs in 
reducing proteinuria in puromycin aminonucleoside (PAN)-induced NS, and 2) Analyzed the potential mech-
anistic pathways for protection in the glomeruli of rats with PAN-induced NS treated with combinations of GC 
Figure 1. Pioglitazone Reduces PAN-Induced Proteinuria and Enhances the Protective Effects of 
Glucocorticoids. Proteinuria was induced in male Wistar rats by single intravenous PAN injections (50 mg/kg)  
on Day 0. Treatment groups also received: (A) low-dose GC (5 mg/kg; n = 13), high-dose GC (15 mg/kg; 
n = 13), and pioglitazone (Pio; 10 mg/kg; n = 13); and (B) high-dose GC (15 mg/kg; n = 13) and combinations 
of pioglitazone with low-dose GC (Pio + low-dose GC; n = 13) or high-dose GC (Pio + high-dose GC; 
n = 4) for 10 days. Urinary protein/creatinine ratios (UPC) are plotted through the course of the experiment 
(Mean ± SEM; *P < 0.05, PAN vs. control; #P < 0.05, treatment vs. PAN; nsP > 0.05; $P < 0.05; determined by 
Two-way ANOVA tukey’s multiple comparison test). (C) Representative gels depicting proteinuria induction 
after PAN injection and reduction after treatments with GC and pioglitazone. Massive amounts of urinary 
albumin after PAN injection were reduced by treatment with high-dose GC and pioglitazone, and even more 
notably reduced by treatment with pioglitazone combined with low-dose GC and high-dose GC (Pio + low-
dose GC and Pio + high-dose GC). Urines were collected daily and equal volumes (4 μl) from selected days were 
analyzed by SDS–polyacrylamide gel electrophoresis and Coomassie Brilliant Blue staining.
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and/or the TZD pioglitazone. and 3) Analyzed the potential of pioglitazone to enhance GC efficacy in reducing 
proteinuria in a child with refractory NS.
Results
Glucocorticoids and Pioglitazone Both Reduce PAN-Induced Proteinuria in Rats. Male Wistar 
rats developed massive proteinuria after a single IV PAN injection of 50 mg/kg, which peaked on day 11 (UPC 
28.0 ± 9.0 mg/mg) (Fig. 1A,C). The control rats received IV saline and maintained baseline levels of urinary pro-
tein (UPC 2.0 ± 0.1 mg/mg). To analyze the ability of GCs to reduce PAN-induced proteinuria, 13 rats/group 
were also treated with intraperitoneal (IP) daily administration of low-dose GC (5 mg/kg), which did not result 
in a significant reduction in proteinuria (25%, P = NS vs. PAN; UPC 21.3 ± 6.0 mg/mg). In contrast, high-dose 
GC (15 mg/kg) reduced proteinuria significantly (79%, P < 0.05 vs. PAN; UPC 7.3 ± 2.1 mg/mg) (Fig. 1A,C). 
Furthermore, enteral daily administration of pioglitazone (10 mg/kg) also resulted in comparable proteinuria 
reduction (61%, P = <0.05 vs. PAN; UPC 12.1 ± 2.7 mg/mg) (Fig. 1A,C). The proteinuria values are also indicated 
in tabular form at three different time points in Table 1. In summary, GC treatment resulted in a reduction in 
PAN-induced proteinuria, but only at a high dose, while pioglitazone treatment alone also resulted in proteinuria 
reduction.
Protective effects of GCs and pioglitazone were also demonstrated in cultured podocytes by restoring the actin 
cytoskeletal arrangement and cell viability (see Supplementary Figure S1).
Pioglitazone Enhances the Efficacy of Glucocorticoids in Reducing PAN-Induced Proteinuria. 
Administration of pioglitazone combined with low-dose GC to PAN-injected rats resulted in further reduction 
in proteinuria at day 11 (63%, P < 0.05 vs. PAN; UPC 11.5 ± 4.9 mg/mg) than with pioglitazone alone (Fig. 1B,C). 
This proteinuria reduction was also statistically similar to the proteinuria reduction induced by high-dose GC 
(79%; P = NS, pioglitazone + low-dose GC vs. high-dose GC), despite a 67% reduction in GC dosing (15 mg/kg 
vs. 5 mg/kg). In addition, treatment with pioglitazone combined with high-dose GC reduced proteinuria even 
more, achieving proteinuria reductions that were statistically similar to control levels (97%, P = NS vs. control; 
UPC 2.7 ± 0.7 mg/mg) (Fig. 1B,C). The proteinuria values are also indicated in tabular form at three different 
time points in Table 1. Moreover, the addition of pioglitazone to either low-dose or high-dose GC did not induce 
changes in body weight or kidney weight (that might be suggestive of edema, a known side effect) compared 
to treatment with GC alone, (see Supplementary Table S1). In summary, pioglitazone enhanced the efficacy of 
low-dose GC in reducing proteinuria, enabling comparable reductions in proteinuria to that of high-dose GC 
despite a 67% reduction in GC dosing. Moreover, the addition of pioglitazone to high-dose GC was able to fur-
ther enhance the efficacy of high-dose GC (97% vs. 79% with high dose-GCs alone), thereby enabling enhanced 
proteinuria reduction to essentially normal control levels.
Pioglitazone and Glucocorticoids Both Restore Synaptopodin Expression in PAN-Injured 
Glomeruli. Evaluation of glomeruli by immunofluorescence microscopy revealed that PAN-induced injury 
resulted in marked reductions in glomerular synaptopodin protein expression, which was restored after treatment 
with high-dose GC, pioglitazone, and pioglitazone + low-dose GC (Fig. 2). These results thus revealed that glo-
merular synaptopodin expression correlated inversely with proteinuria (see Figs 1 and 2 and Table 1).
Pioglitazone and Glucocorticoids Both Enhance the Glomerular Expression of Podocyte 
Markers and Reduce COX-2 Expression. Glomerular mRNA expression of Synpo (encoding for synap-
topodin) and Nphs1 (encoding for nephrin) were both reduced after PAN-induced injury, but were restored after 
treatment with high-dose GC, pioglitazone and pioglitazone + low-dose GC (Fig. 3A,B). In contrast, glomerular 
mRNA expression of Ptgs2 (encoding for COX-2) was increased by PAN injury but also restored to normal levels 
after treatment with high-dose GC, pioglitazone, and pioglitazone + low-dose GC (Fig. 3C).
Phosphorylation of Glomerular Glucocorticoid Receptor and Akt, but not PPARγ, Correlate 
with Glucocorticoid- and Pioglitazone-Induced Reductions in Proteinuria. Glomerular activa-
tion of the GR, as indicated by phosphorylation (p-GR) at Ser 211, was induced by treatment with high-dose GC, 
pioglitazone and pioglitazone + low-dose GC, but not with low-dose GC alone (Fig. 4A). Moreover, the levels of 
glomerular GR activation/phosphorylation correlated inversely with proteinuria in PAN-injected and treated rats 
Group
Proteinuria (UPC; mg/mg) Mean ± SEM
Day 0 Day 7 Day 11
Control 2.10 ± 0.34 2.38 ± 0.17 2.01 ± 0.14
PAN 1.38 ± 0.13 8.22 ± 2.63 27.95 ± 8.95*
PAN+ low-dose GC 1.34 ± 0.10 8.50 ± 1.89 21.26 ± 6.07*
PAN+ high-dose GC 1.34 ± 0.08 4.96 ± 1.06 7.27 ± 2.13#
PAN+ Pio 1.26 ± 0.09 4.94 ± 0.83 12.06 ± 2.73#
PAN+ Pio+ low-dose GC 1.29 ± 0.12 6.91 ± 2.43 11.52 ± 4.88#
PAN+ Pio+ high-dose GC 1.35 ± 0.18 2.00 ± 0.15 2.72 ± 0.67#
Table 1.  Proteinuria values for different treatment groups during the study at different days (expressed as 
UPC ratios). *P < 0.05 vs. control. #P < 0.05 vs. PAN.
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(P = 0.005; Fig. 4D). On the contrary, neither GCs nor pioglitazone blocked the phosphorylation of PPARγ at Ser 
273, it’s known phosphorylation site (Fig. 4B). Moreover, the level of PPARγ phosphorylation (p-PPARγ at Ser 
273) did not show any correlation with proteinuria (Fig. 4E). Furthermore, evaluation of Akt activity as measured 
by phosphorylation (p-Akt) at Ser 473 was increased in all the treatment groups, and the level of phosphorylation 
correlated inversely with proteinuria in PAN-injected and treated rats (P = 0.018; Fig. 4C,F). In summary, p-GR 
and p-Akt, but not p-PPARγ levels inversely correlate with proteinuria in PAN-injected and treated rats.
Discussion
These studies were designed to test the hypothesis that crosstalk between podocyte TZD and GC signaling 
pathways can be exploited to enhance the proteinuria-reducing effects of GCs during NS treatment. Our results 
revealed that pioglitazone alone reduced proteinuria during experimental NS in rats, and also enhanced the effi-
cacy of GC in reducing proteinuria. Furthermore, combining pioglitazone treatment with low-dose GC enabled 
a 67% reduction in GC dosing without any loss of efficacy in reducing proteinuria. In addition, combining pio-
glitazone with high-dose GC notably enhanced the proteinuria-reducing effects of GC to almost normal control 
levels. From a mechanistic perspective, these protective effects were associated with enhancements in podocyte 
markers (Synaptopodin and Nephrin) and a reduction in COX-2 expression in glomeruli. Moreover, glomerular 
phosphorylation of the GR and Akt, but not PPARγ , correlated inversely with proteinuria in both PAN-injured 
and treatment groups. Finally, translation of these findings to a child with refractory NS revealed that the addition 
of pioglitazone to the treatment regimen was associated with marked reductions in both proteinuria (80%) and 
overall immunosuppression (64%) (see Supplementary Figures S2 and S3). These findings together suggest that 
repurposing pioglitazone could potentially enhance the proteinuria-reducing effects of GCs during NS treatment.
Although GCs have been used as the primary therapy for NS for the past 60 years, it was not until 20–30 years 
after their introduction that GCs were first reported to reduce proteinuria in animal disease models15. A few 
recent reports have also noted renoprotective effects for pioglitazone alone in NS models6,7. However, our study 
attempted to significantly extend these findings to compare the in vivo proteinuria-reducing effects of pioglita-
zone alone to that of GC alone, as well as to pioglitazone + low- and high-dose GC combinations. Notably, these 
findings suggest that the addition of pioglitazone may enable a 67% reduction in GC dosing (and thus reduced 
toxicity) without any loss in clinical efficacy in proteinuria reduction. Moreover, the addition of pioglitazone 
might also potentially be able to enhance the clinical efficacy of higher doses of GCs, and could thus also have 
utility in patients with steroid resistant NS. Importantly, in contrast to other TZD members like rosiglitazone in 
the anti-diabetic class of drugs, meta-analysis studies have revealed no increased cardiovascular risk due to pio-
glitazone, and it continues to be widely used in the treatment of diabetes13.
Synaptopodin is an actin-associated protein in podocyte foot processes and its expression is known to 
inversely correlate with glomerular injury during NS16,17. In addition, the expression of another podocyte marker 
Nephrin (Nphs1) is also known to be altered during the development of proteinuria18. In the present study, we 
observed restored and increased glomerular expression of both synaptopodin and nephrin upon treatment with 
pioglitazone and GC after injury. Notably, nephrin expression was increased robustly upon treatment with both 
GC and pioglitazone, which is possibly due to the direct effects of these drugs on the transcription of nephrin 
mRNA via the GC response elements (GRE) and peroxisome proliferator response elements (PPRE), respectively, 
in the promoter region of nephrin gene19,20. We have also extended our previously-reported correlation between 
podocyte Ptgs2 (COX-2) expression and in vitro podocyte injury and recovery seen after treatment with pioglita-
zone and GC to an in vivo model of NS in glomeruli of rats injured with PAN and treated with pioglitazone and 
GC21. Since COX-2 has been widely reported to be involved in glomerular injury, and is known to be regulated by 
trans-repression activities of both GR and PPARγ 22, our results provide additional mechanistic insight into the 
protective pathways induced in podocytes by pioglitazone and GC treatment during NS.
Upon ligand binding, GR undergoes rapid phosphorylation at Ser 211 which is associated with its activation23. 
We have previously reported the ability of pioglitazone, like GCs (although to a lower degree), to modulate GR 
phosphorylation in podocytes10. Extension of these findings in the current study to glomeruli in an in vivo model 
of NS treated with GC and pioglitazone revealed that the proteinuria reductions are directly correlated with GR 
phosphorylation at this site. Furthermore, since PPARγ is the canonical receptor of pioglitazone, we also studied 
Figure 2. Pioglitazone and Glucocorticoids Restore Synaptopodin Expression in PAN-Injured Glomeruli. 
The panels show representative images of the immunofluorescence staining for synaptopodin in the glomeruli of 
kidneys from control, PAN-injured and PAN-injured rats treated with high-dose GC, Pio, and Pio + low-dose GC.
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the status of its phosphorylation at Ser 273 upon treatment with GC and pioglitazone. Phosphorylation at this 
site is believed to be mediated by Cdk5, which has been shown to be blocked by PPARγ agonists, leading to their 
obesity-related effects24. In the current study, we did not find any correlation between phosphorylation levels of 
Figure 3. Pioglitazone and Glucocorticoids Enhance the Glomerular Expression of Podocyte Markers and 
Reduce COX-2 Expression. Total RNA was extracted from glomeruli isolated from control, PAN-injected, and 
PAN-injected rats treated with high-dose GC, Pio, and Pio + low-dose GC (n = 3 per group). Relative mRNA 
levels of (A) Synpo, (B) Nphs1 and (C) Ptgs2 were measured by quantitative reverse transcription–polymerase 
chain reaction and normalized to Gapdh. Data are presented as Mean ± SEM (*P < 0.05 vs. control; #P < 0.05 vs. 
PAN; determined by t-test).
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PPARγ at Ser 273 and proteinuria. This however, does not rule out the role of PPARγ in mediating protective 
effects during NS or renal injury, as has been reported by others8,25. Finally, the crucial role of Akt2 activation by 
mammalian target of rapamycin complex 2 (mTORC2) in podocyte survival has been recently emphasized in a 
mouse model of podocyte-specific deletion of Akt, as well as in human chronic kidney disease26. Therefore, we 
analyzed the relevance of this pathway in PAN-induced NS and treatment by pioglitazone and GC by measuring 
the activation of Akt, as indicated by its phosphorylation at Ser 473 by mTORC2. We not only found that the 
Figure 4. Phosphorylation of the Glomerular Glucocorticoid Receptor and Akt, but not PPARγ, Correlate 
with Glucocorticoid- and Pioglitazone-Induced Reductions in Proteinuria. Total protein was extracted from 
glomeruli isolated from control, PAN-injected, and PAN-injected rats treated with low-dose GC, high-dose GC, 
Pio and Pio + low-dose GC (n = 4 per group). Relative percentage phosphorylation of glucocorticoid receptor 
(GR), PPARγ and Akt was measured by western blotting and densitometry analyses. Values were plotted as 
Mean ± SEM (*P < 0.05 vs. control; #P < 0.05 vs. PAN; determined by t-test) distributed by treatment groups 
(A–C). Percentage phosphorylation was also plotted against the individual proteinuria values and correlations 
were computed by Pearson correlation coefficients (D–F).
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treatment groups had increased glomerular p-Akt compared to the PAN-injured group, but also that glomerular 
p-Akt levels correlated inversely with proteinuria, thus further underscoring the apparent role of this pathway in 
glomerular disease.
In addition to NS, GCs are the first line of therapy for many other diseases, including rheumatoid arthritis, 
asthma and many inflammatory conditions27,28. Similarly, there is an emerging role for pioglitazone and other 
TZDs as novel therapeutic agents for cancer, inflammatory diseases, and arthritis29,30. Our data now identify clear 
beneficial effects from combining pioglitazone with GCs in treating glomerular disease, which may be due to 
crosstalk between TZD- and GC-mediated pathways in podocytes. Others have also recently reported protective 
effects of combinations of pioglitazone and GCs in other disease models such as inflammation, arthritis and lung 
cancer27,28,31. Indeed, combination drug therapy is a common practice in medicine, and often results in improved 
therapeutic effects compared to monotherapy.
Finally, the translation of the results detailed above for the first time to a child with refractory NS is provoc-
ative, albeit anecdotal (see Supplementary Figures S2 and S3). While a single case report certainly cannot imply 
cause and effect, the addition of pioglitazone to the treatment regimen of the child with refractory NS was asso-
ciated with clinically important improvements in his condition. After experiencing eight hospitalizations and 
twenty five IV albumin infusions, and treatment with five relatively toxic immunosuppressive medications over 
two years, initiation of pioglitazone was associated with a subsequent 80% decrease in proteinuria over the ensu-
ing months (without a decrease in eGFR), completely eliminating the need for any subsequent hospitalizations 
or albumin infusions. Moreover, this improvement enabled his treatment team to reduce his overall immunosup-
pression by 64%, thereby markedly reducing his ongoing exposure to potentially toxic medications and reducing 
his risk for infection (see Supplementary Tables S2A and S2B). While he did not enter into complete remission, 
the combination of elimination of hospitalizations with the marked reduction in overall immunosuppression has 
greatly enhanced his quality of life, reduced his healthcare utilization and expenses, and potentially reduced his 
risk for progression to end-stage kidney disease. Furthermore, the model used in this study for the calculation of 
overall immunosuppression (Total ISS) could easily be personalized for other patients or diseases based on the 
specific immunosuppressive medications prescribed.
These studies had a few notable limitations. First, the experiments were designed to determine if pioglita-
zone is able to enhance the ability of GC to protect against proteinuria, and not specifically to analyze its ability 
to enhance resolution of existing proteinuria. In addition, the studies were only designed to analyze short term 
effects of pioglitazone and GC on proteinuria reduction, and not their ability to induce prolonged reductions in 
proteinuria.
In summary, the protective effects of pioglitazone and GC reported here in an in vivo model of NS, combined 
with the clinical improvements seen in the above child, suggest two intriguing possibilities: 1) That pioglitazone 
could potentially be used to enable reduced dosing (and toxicity) of GC without a reduction in clinical efficacy, 
and 2) That pioglitazone could potentially be used to enhance the clinical efficacy of GCs in the setting of clinical 
steroid resistance. Hopefully, a future prospective clinical trial will enable validation of the potential repurposing 
of pioglitazone as a GC supplement for NS, and possibly other diseases treated with GCs.
Methods
Animal Study Design. The performed studies were approved by the Institutional Animal Care and Use 
Committee at Nationwide Children’s Hospital and all the experiments were performed in accordance with the 
approved guidelines. Proteinuria was induced in male Wistar rats weighing ~150–200 g by single intravenous (IV) 
PAN (Sigma-Aldrich, St. Louis, MO) injection (50 mg/kg) on Day 0, while the control group received IV saline 
injections (n = 13). A group of PAN injected rats (n = 13) were left untreated and received sham oral gavage vehi-
cle solution (0.5% methylcellulose, 0.025% Tween-20), while the treatment groups (n = 13/group) also received: 
(i) Low-dose GC (Methylprednisolone; 5 mg/kg; n = 13; Solu-Medrol, Pfizer Inc., New York, NY) by intraperi-
toneal (IP) injection daily, (ii) High-dose GC (15 mg/kg; n = 13), (iii) Pioglitazone (Pio; 10 mg/kg; n = 13; Actos; 
Takeda, Deerfield, IL) by oral gavage daily, (iv) Combined low-dose GC + pioglitazone [(Pio + low-dose GC; 
n = 13), and (v) Combined high-dose GC + pioglitazone (Pio + high-dose GC; n = 4)] starting at Day 0. Two 
control rats also received pioglitazone alone (10 mg/kg) by oral gavage daily with no PAN injection. Urine samples 
were collected at baseline (prior to injury) and daily during the study for analysis. The rats were weighed daily and 
sacrificed on Day 11 at the point of expected peak proteinuria and the kidneys harvested, weighed and processed 
for paraffin sectioning and glomerular isolation.
Urine Analyses. Albuminuria was monitored by analyzing 4 μl urine samples taken at Days 0, 2, 4, 7, 8, 9, 10 
and 11 for the presence of albumin by SDS-PAGE and Coomassie Brilliant Blue staining. Urine protein:creatinine 
ratios (UPC) were measured by Antech Diagnostics GLP (Morrisville, NC), which is fully compliant with Good 
Laboratory Practice (GLP) regulations.
Glomerular Isolation. Glomeruli were isolated using a standard sequential sieving method, as described 
previously21,32 and the resulting preparations were washed with PBS and assessed under a light microscope, 
which confirmed ~95% glomeruli. One half of the glomerular preparation was suspended in RLT buffer (Qiagen, 
Germantown, MD) containing β -Mercaptoethanol (Sigma-Aldrich) and homogenized with a 21 gauge needle for 
RNA isolation as described below. Protein extracts were prepared from the other half of the glomerular prepara-
tion in Tissue Protein Extraction Reagent (TPER; Thermo Fisher Scientific, Waltham, MA).
RNA Extraction and Real Time Polymerase Chain Reaction. Total RNA from isolated glomeruli 
was isolated using the RNeasy kit (Qiagen) according to the manufacturer’s instructions. The purity and yield 
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of RNA was determined by measuring the absorbance at 260 and 280 nm and used for quantitative reverse 
transcribed-polymerase chain reaction (qRT-PCR), as described previously10. Briefly, 1 μg of RNA was subjected 
to DNase (Ambion, Thermo Fisher Scientific) digestion at 37 °C for 30 min followed by DNase inactivation with 
5 mM EDTA at 75 °C for 10 min. cDNA was then synthesized from 1 μg DNase-treated RNA in a 20 μl reaction 
using iScript reverse transcriptase (Bio-Rad, Hercules, CA), according to manufacturer’s protocol. The Synpo, 
Nphs1, Ptgs2 and Gapdh mRNAs were quantified by qRT-PCR using the SYBR green method on an iQ5 thermal 
cycler (Bio-Rad) using forward and reverse primers (Table 2). The PCR conditions were as follows: 1 cycle at 95 °C 
for 3 min, 40 cycles at 95 °C for 10 sec, and 55 °C for 10 sec, followed by a melt curve analysis. The amplification 
efficiency of each primer pair was then measured by plotting the efficiency curve of serial dilutions of selected 
cDNA samples. Values were normalized to the housekeeping gene Gapdh and plotted as fold changes relative to 
vehicle control treatments.
Western Blotting. Protein extracts (10–20 μg) were separated by SDS-polyacrylamide gel electropho-
resis (PAGE), and transferred to nitrocellulose membrane (Bio-Rad). Membranes were blocked for 1 hour 
with 5% milk in PBS containing 0.1% Tween 20 followed by incubation in primary antibody overnight 
[anti-phospho-GR (Ser211), anti-PPARγ , anti-phospho Akt (Ser 473) and anti-Akt (Cell Signaling Technology, 
Danvers, MA); anti-GR (Santa Cruz Biotechnology, Dallas, TX); anti-phospho-PPARγ (Ser 273) (Bioss Inc., 
Woburn, MA); and anti-β -Actin (Sigma-Aldrich)]. Following four washes, blots were incubated in horserad-
ish peroxidase-conjugated secondary antibodies against mouse or rabbit IgG (Jackson Immuno Research 
Laboratories, West Grove, PA) for 2 hours at room temperature. Protein bands were detected on X-ray film using 
the ECL chemiluminescence reagent (GE Healthcare Bio-Sciences, Pittsburgh, PA). X-ray films were scanned 
using a calibrated ArtixScan M1 transillumination scanner (Microtek Lab Inc., Cerritos, CA) controlled by the 
ScanWizard Pro program (version 7.042) and densitometric analysis of the integrated band density was per-
formed using ImageJ (version 1.39, standard settings; http://rsb.info.nih.gov/ij/).
Immunofluorescence Staining. Kidneys were examined by indirect immunofluorescence on 4-micron 
thick paraffin sections. The sections were deparaffinized with xylene and rehydrated in graded ethanol. Antigen 
retrieval was performed by boiling the slides in 10 mM sodium citrate followed by PBS-Tween (0.5% Tween-20) 
wash. Blocking was done with Super Block (Scytek Labs Inc., Logan, UT) for 6 min at 37 °C, followed by incuba-
tion with anti-synaptopodin primary antibody (Santa Cruz Biotechnology) in 5% super-block at 4 °C overnight 
at 1:100 dilution. Sections were washed three times for 10 min each with 2.5% Super Block in PBS-Tween (0.5% 
Tween-20) and incubated with fluorescent secondary antibody (Alexa Flour, 2 ug/ml; Invitrogen, Carlsbad, CA) 
in 5% Super Block in PBS for 1 hour at room temperature. Sections were then washed three times for 10 min 
each with 2.5% Super Block in PBS-Tween (0.5% Tween-20), mounted with Prolong Gold Antifade Reagent 
(Invitrogen). Kidney sections from the groups were viewed and imaged with exposures within 250–600 ms with 
an Axio Scope fluorescent microscope (Carl Zeiss Microscopy GmbH, Jena, Germany).
Statistical Analyses. Statistical differences were determined by the unpaired Student’s t-test for single com-
parisons and two-way ANOVA for multiple comparisons, using the GraphPad Prism software version 6.00 for 
Windows. P-values < 0.05 were considered to be significant and all data are presented as mean ± SEM.
References
1. MacHardy, N. et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol. 24, 2193–2201 (2009).
2. Ponticelli, C. et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney 
Dis. 34, 618–625 (1999).
3. Greenbaum, L. A., Benndorf, R. & Smoyer, W. E. Childhood nephrotic syndrome–current and future therapies. Nat Rev Nephrol. 8, 
445–458 (2012).
4. Sarafidis, P. A., Stafylas, P. C., Georgianos, P. I., Saratzis, A. N. & Lasaridis, A. N. Effect of thiazolidinediones on albuminuria and 
proteinuria in diabetes: a meta-analysis. Am J Kidney Dis. 55, 835–847 (2010).
5. Liu, H. F. et al. Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit 
diaphragm protection. Nephrology (Carlton). 15, 75–83 (2010).
6. Zuo, Y. et al. Protective effects of PPARgamma agonist in acute nephrotic syndrome. Nephrol Dial Transplant. 27, 174–181 (2012).
7. Yang, H. C., Ma, L. J., Ma, J. & Fogo, A. B. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte 
injury-associated sclerosis. Kidney Int. 69, 1756–1764 (2006).
8. Henique, C. et al. Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-
Activated Receptor gamma Essential for Resistance to Crescentic GN. J Am Soc Nephrol. 27, 172–188 (2016).
9. Kanjanabuch, T. et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 71, 1232–1239 (2007).
10. Agrawal, S., Guess, A. J., Benndorf, R. & Smoyer, W. E. Comparison of direct action of thiazolidinediones and glucocorticoids on 
renal podocytes: protection from injury and molecular effects. Mol Pharmacol. 80, 389–399 (2011).
Gene Genbank ID Forward Reverse
Synpo NM_021695 caaacccaacactccaagcg tgcatgccaatgagcagaga
Nphs1 NM_022628 tgctctttgcagttggtggt tcctgatcctgtcctccgac
Ptgs2 NM_017232 attgctggccgggttgctgg tcagggagaagcgtttgcggt
Gapdh NM_017008 tgtatccgttgtggatctga cctgcttcaccaccttcttga
Table 2.  Genes and Their Respective Primers Used in This Study. Sequences are in 5′ to 3′ direction.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:24392 | DOI: 10.1038/srep24392
11. Guan, Y. & Breyer, M. D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 
60, 14–30 (2001).
12. Miglio, G. et al. Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms 
of action. Br J Pharmacol. 167, 641–653 (2012).
13. Soccio, R. E., Chen, E. R. & Lazar, M. A. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 
20, 573–591 (2014).
14. Beck, I. M. et al. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and 
phosphatases. Endocr Rev. 30, 830–882 (2009).
15. Kawamura, T., Yoshioka, T., Bills, T., Fogo, A. & Ichikawa, I. Glucocorticoid activates glomerular antioxidant enzymes and protects 
glomeruli from oxidant injuries. Kidney Int. 40, 291–301 (1991).
16. Srivastava, T., Garola, R. E., Whiting, J. M. & Alon, U. S. Synaptopodin expression in idiopathic nephrotic syndrome of childhood. 
Kidney Int. 59, 118–125 (2001).
17. Barisoni, L., Kriz, W., Mundel, P. & D’Agati, V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of 
collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 10, 51–61 (1999).
18. Guan, N., Ding, J., Deng, J., Zhang, J. & Yang, J. Key molecular events in puromycin aminonucleoside nephrosis rats. Pathol Int. 54, 
703–711 (2004).
19. Benigni, A. et al. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: 
molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol. 17, 1624–1632 (2006).
20. Yamauchi, K. et al. Screening and identification of substances that regulate nephrin gene expression using engineered reporter 
podocytes. Kidney Int. 70, 892–900 (2006).
21. Agrawal, S., Guess, A. J., Chanley, M. A. & Smoyer, W. E. Albumin-induced podocyte injury and protection are associated with 
regulation of COX-2. Kidney Int. 86, 1150–1160 (2014).
22. Li, M. D. & Yang, X. A Retrospective on Nuclear Receptor Regulation of Inflammation: Lessons from GR and PPARs. PPAR Res. 
2011, 742785 (2011).
23. Tasker, J. G., Di, S. & Malcher-Lopes, R. Minireview: rapid glucocorticoid signaling via membrane-associated receptors. 
Endocrinology. 147, 5549–5556 (2006).
24. Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature. 477, 
477–481 (2011).
25. Miglio, G. et al. The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in 
decreasing podocyte injury. Br J Pharmacol. 162, 111–125 (2011).
26. Canaud, G. et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med. 19, 
1288–1296 (2013).
27. Yamamoto, A., Kakuta, H. & Sugimoto, Y. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by 
peroxisome proliferator-activated receptor gamma agonist in mice. Int Immunopharmacol. 22, 204–208 (2014).
28. Suke, S. G., Negi, H., Mediratta, P. K., Banerjee, B. D. & Sharma, K. K. Anti-arthritic and anti-inflammatory activity of combined 
pioglitazone and prednisolone on adjuvant-induced arthritis. Eur J Pharmacol. 718, 57–62 (2013).
29. Koeffler, H. P. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 9, 1–9 (2003).
30. Ialenti, A. et al. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol 
Pharmacol. 67, 1620–1628 (2005).
31. Fu, H. et al. Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J 
mice. Mol Carcinog. 50, 913–921 (2011).
32. Smoyer, W. E., Gupta, A., Mundel, P., Ballew, J. D. & Welsh, M. J. Altered expression of glomerular heat shock protein 27 in 
experimental nephrotic syndrome. J Clin Invest. 97, 2697–2704 (1996).
Acknowledgements
We are grateful to Bryce A. Kerlin, Amanda Waller, Terri Shaffer, Chelsea Bittler and Ruma Pengal for their 
valuable contributions to the in vivo studies. The present study was supported by a grant from the National 
Institute of Health NIDDK R01 (DK 095059) to WES.
Author Contributions
S.A. conceived and designed the study, performed experiments, analyzed and interpreted the data, drafted the 
manuscript and prepared the figures and tables. M.A.C. performed the in vivo animal experiments and collected 
the data. D.W. collated the patient data, analyzed it and participated in the preparation of the case report and 
associated figure and tables. X.N. participated in performing immunofluorescence experiments. T.K. participated 
in performing western blotting experiments. A.J.G. participated in the experiments with glomerular isolation. 
R.B. participated in the experiments with glomerular isolation and in in vivo study design. G.H. treated his patient 
with pioglitazone and participated in clinical data collection and writing the case report. W.E.S. designed the 
study, interpreted the data and participated in writing and editing the manuscript. All the authors approve of the 
final version of the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Agrawal, S. et al. Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in 
Experimental Nephrotic Syndrome. Sci. Rep. 6, 24392; doi: 10.1038/srep24392 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
